Association of glycation gap with mortality and vascular complications in diabetes wolverhampton diabetes

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 3247-3253

  Nayak, Ananth U ^a,b   Nevill, Alan M ^c   Bassett, Paul ^d   Singh, Baldev M ^a  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^c UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^d Statsconsultancy Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSAMINE; HEMOGLOBIN A1C; INSULIN;

ADULT; AGE; AGED; ANALYTIC METHOD; ARTICLE; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG USE; ETHNIC GROUP; FEMALE; GLYCATION; GLYCATION GAP; GLYCEMIC CONTROL; HUMAN; MACROVASCULAR DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; MORTALITY; OBESITY; OUTCOME ASSESSMENT; SEX; SMOKING; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED;

EID: 84891845824     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1040     Document Type: Article

References (42)

1. Nayak AU, Holland MR, Macdonald DR, Nevill A, Singh BM. Evidence for consistency of the glycation gap in diabetes. Diabetes Care 2011;34:1712-1716
2. Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care 2003;26: 163-167
3. Hempe JM, Gomez R, McCarter RJ Jr, Chalew SA. High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications 2002; 16:313-320
4. Hudson PR, Child DF, Jones H, Williams CP. Differences in rates of glycation (glycation index) may significantly affect individual HbA1c results in type 1 diabetes. Ann Clin Biochem 1999;36:451-459
5. Gould BJ, Davie SJ, Yudkin JS. Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Clin Chim Acta 1997;260:49-64
6. Dagogo-Jack S. Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum Nat Rev Endocrinol 2010;6:589-593
7. Cohen RM, Franco RS, Khera PK, et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008;112: 4284-4291
8. Khera PK, Joiner CH, Carruthers A, et al. Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes 2008;57:2445-2452
9. Soranzo N, Sanna S, Wheeler E, et al. Common variants at 10 genomic loci influence hemoglobin A1c levels via glycemic and nonglycemic pathways. Diabetes 2010;59:3229-3239
10. Delpierrre G, Vertommen D, CommuniD, Rider MH, Van Schaftingen E. Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin. J Biol Chem 2004;279:27613-27620
11. Mohas M, Kisfali P, Baricza E, et al. A polymorphism within the fructosamine-3-kinase gene is associated with HbA1c levels and the onset of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2010;118:209-212
12. Delpierre G, Veiga-da-Cunha M, Vertommen D, Buysschaert M, Van Schaftingen E. Variability in erythrocyte fructosamine 3-kinase activity in humans correlates with polymorphisms in the FN3K gene and impacts on haemoglobin glycation at specific sites. Diabetes Metab 2006;32: 31-39
13. Chan JC, Yeung VT, Cheung CK, Swaminathan R, Cockram CS. The interrelationships between albuminuria, plasma albumin concentration and indices of glycaemic control in non-insulin-dependent diabetes mellitus. Clin Chim Acta 1992; 210:179-185
14. Perry HM 3rd, Morley JE, Miller DK. Serum fructosamine and obesity. Diabetes Care 1999;22:1596-1597
15. Sacks DB, Nathan DM, Lachin JM. Gaps in the glycation gap hypothesis. Clin Chem 2011;57:150-152
16. Retinopathy grading recommendations by the English National Screening Programme for Diabetic Retinopathy (ENSPDR). Available from http://www. retinalscreening.nhs.uk/pages/). Accessed 27 September 2011
17. Marshall SM. Screening for microalbuminuria: whichmeasurement? Diabet Med 1991;8:706-711
18. Schleicher ED, Mayer R, Wagner EM, Gerbitz KD. Is serum fructosamine assay specific for determination of glycated serumprotein? Clin Chem1988;34:320-323
19. Macdonald DR, Hanson AM, Holland MR, Singh BM. Clinical impact of variability in HbA1c as assessed by simultaneously measuring fructosamine and use of error grid analysis. Ann Clin Biochem 2008;45: 421-425
20. Cohen RM, Snieder H, Lindsell CJ, et al. Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care 2006;29:1739-1743
21. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853
23. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986
24. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93: 1143-1152
25. Rodriguez-Segade S, Rodriguez J, Cabezas-Agricola JM, Casanueva FF, Camiña F. Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (HbA1c). Clin Chem 2011;57:264-271
26. McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 2004;27:1259-1264
27. The Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-841
28. Holman RR, Paul SK, Bethel MA, MatthewsDR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
29. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a metaanalysis of randomised controlled trials. Lancet 2009;373:1765-1772
30. Boussageon R, Bejan-Angoulvant T, Saadatian-ElahiM, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169
31. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009;151:394-403
32. Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 2010;7:369-375
33. DuckworthW, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360: 129-139
34. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
35. ACCORD Study Group; Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-828
36. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-489
37. Lachin JM, Genuth S, Nathan DM, Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes 2007;56:1913-1921
38. Baker JR, Metcalf PA, Holdaway IM, Johnson RN. Serum fructosamine concentration as measure of blood glucose control in type I (insulin dependent) diabetes mellitus. Br Med J (Clin Res Ed) 1985;290:352-355
39. Vos FE, SchollumJB, Coulter CV, Manning PJ, Duffull SB, Walker RJ. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. Nephrology (Carlton) 2012;17:182-188
40. Chalew SA, McCarter RJ, Thomas J, Thomson JL, Hempe JM. A comparison of the glycosylation gap and hemoglobin glycation index in patients with diabetes. J Diabetes Complications 2005;19:218-222
41. Zoungas S, Chalmers J, Ninomiya T, et al.; ADVANCE Collaborative Group. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012;55:636-643
42. Rutter MK. Low HbA1c and mortality: causation and confounding. Diabetologia 2012;55:2307-2311